Summit Therapeutics, Inc. (SMMT)
17.60
+0.48
(+2.77%)
USD |
NASDAQ |
Sep 04, 16:00
17.59
-0.02
(-0.09%)
After-Hours: 20:00
Summit Therapeutics Accounts Payable (Quarterly) : 22.90M for June 30, 2026
Accounts Payable (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Accounts Payable (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.90M |
| March 31, 2026 | 27.55M |
| December 31, 2025 | 20.29M |
| September 30, 2025 | 22.24M |
| June 30, 2025 | 22.98M |
| March 31, 2025 | 4.994M |
| December 31, 2024 | 4.636M |
| September 30, 2024 | 3.252M |
| June 30, 2024 | 3.34M |
| March 31, 2024 | 6.371M |
| December 31, 2023 | 2.667M |
| September 30, 2023 | 3.314M |
| June 30, 2023 | 0.987M |
| March 31, 2023 | 0.71M |
| December 31, 2022 | 0.355M |
| September 30, 2022 | 1.431M |
| June 30, 2022 | 3.574M |
| March 31, 2022 | 6.959M |
| December 31, 2021 | 4.374M |
| September 30, 2021 | 5.875M |
| June 30, 2021 | 6.949M |
| March 31, 2021 | 4.114M |
| December 31, 2020 | 6.14M |
| September 30, 2020 | 2.493M |
| Date | Value |
|---|---|
| June 30, 2020 | |
| March 31, 2020 | 12.59M |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | 11.66M |
| October 31, 2018 | 6.787M |
| July 31, 2018 | 8.639M |
| April 30, 2018 | 12.03M |
| January 31, 2018 | 12.70M |
| October 31, 2017 | 5.200M |
| July 31, 2017 | 4.627M |
| April 30, 2017 | 4.130M |
| January 31, 2017 | 5.012M |
| October 31, 2016 | 3.856M |
| July 31, 2016 | 4.397M |
| April 30, 2016 | 4.582M |
| January 31, 2016 | 1.016M |
| October 31, 2015 | 4.323M |
| July 31, 2015 | 4.156M |
| April 30, 2015 | 4.16M |
| January 31, 2015 | 1.795M |
Accounts Payable Definition
Represents amounts due to suppliers of goods and/or services used in the company's operations, generally not interest-bearing, and as yet unpaid at the prior fiscal period-end and expected to be paid within the current period. Data for this field is generally not available prior to 1989.
Accounts Payable (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Accounts Payable (Quarterly) Benchmarks
| NovelStem International Corp. | 0.00 |
| Brainstorm Cell Therapeutics, Inc. | 7.488M |
| Kezar Life Sciences, Inc. | 0.273M |
| Protara Therapeutics, Inc. | 4.663M |
| Clene, Inc. | 1.142M |